The Immune System – News and Features

Procognia will combine its protein array technology with GSK’s fluorescently-labelled kinase inhibitors to enable GSK to profile its kinase hits in-house.

Calando has published results of the non-human primate study to use multiple, systemic dosing with its lead siRNA therapeutic candidate.

University of Michigan Health System researchers says that there findings could help with transplant rejection.

VentiRx acquires exclusive worldwide rights to toll-like receptor program from Array to develop candidates in oncology and allergy.

The Company’s immunogenicity screening tool for protein therapeutics has been granted a European patent.

Senior scientist Dr Mike Gresser, with experience at Amgen and Merck will assist the drive to develop new personalised medicines.

Lorry I. Lokey, the founder of Business Wire will give $33 million to help build new laboratories for Stanford’s Institute for Stem Cell Biology and Regenerative Medicine.

Pluristem believes their PLX cells are immunosuppressive and could develop products for a variety of therapeutic needs: regenerative medicine, physiological diseases and immune diseases.

Evotec will use its medicinal and computational chemistry expertise to develop potent inhibitors for IL-6 using Interprotein’s number of hit molecules based on in-silico drug design.

Researchers involved in the Influenza Genome Sequencing Project have sequenced the genomes of more than 2,000 influenza viruses.